

Rhythm Biosciences enters a US marketing partnership with Catch Bio, a cancer prevention platform

Highlights

- ✓ Rhythm and Catch Bio have entered into a marketing agreement to introduce the geneType™ Cancer Risk Assessment Test to Catch Bio's growing US member base.
- ✓ geneType™ will enhance Catch Bio's Cancer Prevention Platform by providing clinically validated polygenic risk assessment across up to six cancers.
- ✓ This partnership represents another step forward in Rhythm's US market expansion strategy and supports the growing commercial acceptance of geneType™.

Melbourne, Australia, 9th December 2025: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce it has signed a marketing partnership with Catch Bio, Inc, a leading Cancer prevention Platform focused on empowering individuals to identify, analyse and actively manage their cancer risk. geneType™ integrates an individual's genetic profile, clinical factors, and family history to generate personalised cancer risk insights across breast, colorectal, prostate, melanoma, ovarian, pancreatic cancer, and other major diseases.

Catch Bio's AI-driven risk model incorporates more than five hundred validated lifestyle and environmental risk factors from multiple peer-reviewed studies. Integrating geneType™ with their platform enhances the precision of risk assessment and delivers a more comprehensive risk profile to users looking to take proactive steps in cancer prevention.

The partnership further supports Rhythm's strategy to build an early commercial presence in the US and provides an additional channel demonstrating growing market acceptance and clinical utility of geneType™.

Early indicators from US clinicians, health practices, and platform partners continue to validate the demand for accessible, multi-disease genetic risk assessment. Integration into a technology-enabled prevention platform such as Catch Bio represents a meaningful commercial milestone as Rhythm expands its footprint in a key global market.

Rhythm CEO Dr. David Atkins said: "This partnership furthers our commitment to the early detection of cancer. By offering both Catch Bio's AI-model and Rhythm's clinically validated geneType™ test, Catch Bio will increase their overall power of risk assessment. We are excited to enter into this important partnership to expand Rhythm's presence in the US."

Directors

Catch Bio Founder and COO Jane Corbett said: “Our mission is to increase awareness and action in Cancer Prevention. We are proud to partner with Rhythm and make their geneType™ tests available to our members to improve their management of cancer risk.”

About Catch Bio Inc

- Catch Bio (www.catchbio.com) was formed in 2023 and launched their platform in 2025. Through 2026 they will continue to refine their platform designed to allow their members to know and proactively manage their Cancer risk.
- By drawing from multiple scientific disciplines, Catch Bio has created an AI machine learning capability for cancer risk, a powerful and comprehensive risk model, and most importantly, an action plan that translates the outputs into real world cancer risk reduction.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.